ARTICLE | Clinical News
Zadaxin thymosin alpha 1: Began Phase III trials
January 16, 2001 8:00 AM UTC
SciClone Pharmaceuticals Inc. (SCLN), San Mateo, Calif. Product: Zadaxin thymosin alpha 1 Business: Cancer Therapeutic category: Immune modulation Target: T cells and NK cells Description: Synthetic ...